Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 5 | 6 |
| List of Tables | 7 | 2 |
| List of Figures | 9 | 2 |
| Taiwan Pharmaceutical Market Outlook 2013 Introduction | 11 | 1 |
| Taiwan Pharmaceutical Market | 11 | 1 |
| Taiwan Pharmaceutical Market Outlook 2013 Investment Environment | 12 | 6 |
| Government and Political Environment | 12 | 1 |
| Taiwan Economic Outlook | 12 | 2 |
| Foreign Trade and Investment | 14 | 2 |
| Investment Incentives Government Boosting the Biotech Sector | 16 | 1 |
| Act for the Development of Biotech and New Pharmaceuticals Industry (2007) | 16 | 1 |
| Diamond Action Plan for Biotechnology Takeoff (2009) | 16 | 1 |
| Biotechnology Venture Capital Fund Worth TWD60 Billion ($1.8 Billion) to be Injected into the Sector | 16 | 1 |
| International Appraisal and Membership | 17 | 1 |
| Patent Prosecution Highway Pilot program | 17 | 1 |
| Pharmaceutical Inspection Convention and Inspection Cooperation Scheme | 17 | 1 |
| Taiwan Pharmaceutical Market Outlook 2013 Healthcare System | 18 | 27 |
| Healthcare System | 18 | 1 |
| Department of Health | 18 | 1 |
| Bureau of National Health Insurance | 19 | 1 |
| Health Insurance Coverage | 20 | 2 |
| Health Insurance System Challenges | 22 | 1 |
| Health Policy Initiatives | 23 | 1 |
| Healthcare Expenditure | 24 | 1 |
| Healthcare Spending | 24 | 1 |
| National Healthcare Expenditure | 24 | 1 |
| Healthcare Expenditure as Percentage of GDP | 25 | 2 |
| Healthcare Expenditure by Type of Service | 27 | 1 |
| Healthcare Expenditure on Pharmaceutical Products | 28 | 2 |
| Public Health Expenditure | 30 | 2 |
| Healthcare Infrastructure | 32 | 1 |
| Healthcare Facilities | 32 | 1 |
| Hospitals and Other Facilities | 32 | 1 |
| Public and Private Hospitals | 33 | 1 |
| Healthcare Coverage | 33 | 1 |
| Bed to Population Ratio | 33 | 2 |
| Healthcare Personnel | 35 | 1 |
| Physicians to Population Ratio | 35 | 2 |
| Nurses to Population Ratio | 37 | 1 |
| Pharmacists-to-Population Ratio | 38 | 1 |
| Population Health | 39 | 1 |
| Demographics | 39 | 1 |
| Gender Ratio | 39 | 1 |
| Aging Trends | 40 | 1 |
| Life Expectancy | 41 | 2 |
| Mortality | 43 | 1 |
| Mortality Rate | 43 | 1 |
| Causes of Mortality | 43 | 2 |
| Taiwan Pharmaceutical Market Outlook 2013 Regulatory Landscape | 45 | 7 |
| Drug Pricing and Reimbursement | 45 | 1 |
| Drug Reimbursement | 45 | 1 |
| Pricing Policies | 45 | 2 |
| Pricing Trends | 47 | 1 |
| Challenges in the Reimbursement Process | 48 | 1 |
| Price Volume Survey | 48 | 1 |
| Provider Price Reimbursement Gap | 48 | 1 |
| Product Grouping Leading to High Reimbursement Pricing for Generics | 48 | 1 |
| Drug Expenditure Target | 49 | 1 |
| Policy and Regulatory Environment in Taiwan | 49 | 1 |
| New Drug Approval | 49 | 1 |
| Amendments to Registration Process for New Drugs | 49 | 1 |
| Further Modifications to Marketing Approval Process of New Drugs | 49 | 1 |
| Intellectual Property Rights | 50 | 1 |
| Taiwan Intellectual Property Office | 50 | 1 |
| IPR Status | 50 | 1 |
| IPR Challenges | 51 | 1 |
| Taiwan Pharmaceutical Market Outlook 2013 Market Overview | 52 | 28 |
| Pharmaceutical Market Overview | 52 | 1 |
| Pharmaceutical Market Size | 53 | 1 |
| Market Segments | 54 | 1 |
| Generic Drugs | 54 | 2 |
| Biologics/Biosimilars | 56 | 1 |
| Over-the-Counter Drugs | 57 | 1 |
| Key Therapeutic Areas | 58 | 3 |
| Respiratory Diseases | 61 | 3 |
| Digestive Diseases | 64 | 3 |
| Genitourinary Diseases | 67 | 2 |
| Circulatory Diseases | 69 | 3 |
| Malignant Neoplasms | 72 | 1 |
| Overview | 72 | 3 |
| High Prevalence of Cancer | 75 | 1 |
| Government Policy Focuses on Cancer Drugs | 76 | 1 |
| Emerging Areas | 77 | 1 |
| Orphan Drugs | 77 | 1 |
| Drug Distribution and Pharmaceutical Supply Chain | 78 | 1 |
| Spending in Pharmaceutical R&D | 79 | 1 |
| Taiwan Pharmaceutical Market Outlook 2013 Competitive Landscape | 80 | 37 |
| Key Foreign Entities | 80 | 1 |
| Pfizer | 80 | 1 |
| Company Overview | 80 | 1 |
| Financial Performance | 81 | 1 |
| Major Products | 82 | 1 |
| Pipeline Products | 83 | 2 |
| Sanofi | 85 | 1 |
| Company Overview | 85 | 1 |
| Financial Performance | 86 | 1 |
| Major Products | 87 | 1 |
| Pipeline Products | 88 | 1 |
| Recent Developments | 88 | 1 |
| Novartis | 89 | 1 |
| Company Overview | 89 | 1 |
| Financial Performance | 90 | 1 |
| Major Products | 91 | 1 |
| Product Pipeline | 92 | 1 |
| Recent Developments | 93 | 1 |
| GlaxoSmithKline | 94 | 1 |
| Company Overview | 94 | 2 |
| Financial Performance | 96 | 1 |
| Major Products | 97 | 1 |
| Product Pipeline | 98 | 1 |
| Recent Developments | 99 | 1 |
| Key Domestic Players | 100 | 1 |
| The China Chemical &Pharmaceutical Company | 100 | 1 |
| Overview | 100 | 1 |
| Financial Performance | 101 | 1 |
| Major Products | 102 | 1 |
| Recent Developments | 103 | 1 |
| Standard Chemicals &Pharmaceuticals Co. Ltd. | 103 | 1 |
| Company Overview | 103 | 1 |
| Financial Performance | 103 | 2 |
| Major Products | 105 | 1 |
| Recent Developments | 106 | 1 |
| Yung Shin Pharmaceutical. Ind. Co. Ltd. | 106 | 1 |
| Company Overview | 106 | 1 |
| Financial Performance | 107 | 1 |
| Major Products | 108 | 1 |
| Recent Developments | 109 | 1 |
| ScinoPharm Taiwan | 109 | 1 |
| Company Overview | 109 | 1 |
| Financial Performance | 110 | 2 |
| Major Products | 112 | 1 |
| Recent Developments | 112 | 2 |
| TTY Biopharm Company Limited | 114 | 1 |
| Company Overview | 114 | 1 |
| Financial Performance | 114 | 1 |
| Major Products | 115 | 1 |
| Pipeline Products | 116 | 1 |
| Recent Developments | 116 | 1 |
| Taiwan Pharmaceutical Market Outlook 2013 Market Dynamics | 117 | 2 |
| Industry Drivers and Opportunities | 117 | 1 |
| Barriers to Entry | 117 | 1 |
| Recent Industry Activity and Consolidation | 118 | 1 |
| Taiwan Pharmaceutical Market Outlook 2013 the Way Forward | 119 | 2 |
| Key Insights | 119 | 1 |
| Market Opportunities | 119 | 1 |
| Future Market Outlook | 120 | 1 |
| Taiwan Pharmaceutical Market Outlook 2013 Appendix | 121 | 8 |
| Market Definitions | 121 | 1 |
| Abbreviations | 121 | 2 |
| Bibliography | 123 | 3 |
| Research Methodology | 126 | 3 |
| Coverage | 127 | 1 |
| Secondary Research | 127 | 1 |
| Primary Research | 127 | 1 |
| Expert Panel Validation | 128 | 1 |
| Contact Us | 128 | 1 |
| Disclaimer | 128 | 1 |
